Skip to Content

Thermo Fisher Scientific Inc TMO

Morningstar Rating
$607.14 +12.64 (2.13%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Thermo Fisher Earnings: More of the Same, Second Half Should Return to Growth

We are maintaining our $630 fair value estimate for wide-moat Thermo Fisher following its second-quarter results. Organic revenue declined 1% in the quarter but was effectively flat once adjusted for the remainder of the covid-19 revenue in the prior year. Performance on the top and bottom lines is in line with our forecast, and the company is now set to recover in the second half of the year.

Price vs Fair Value

TMO is trading at a 852% premium.
Price
$607.14
Fair Value
$558.00
Uncertainty
Medium
1-Star Price
$374.20
5-Star Price
$334.00
Economic Moat
Bsrm
Capital Allocation
Qqvnsglyhc

Bulls Say, Bears Say

Bulls

Thermo Fisher is among the industry's best when it comes to cost control. As near-term spending is constrained, the company's margins show exceptional resilence.

Bears

The company was able to fuel its acquisition spree via access to extremely inexpensive debt. Generating excess returns on acquisitions in a current less favorable interest-rate environment might be more challenging.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TMO is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$594.50
Day Range
$599.30614.65
52-Week Range
$415.60614.65
Bid/Ask
$583.76 / $622.00
Market Cap
$231.76 Bil
Volume/Avg
2.7 Mil / 1.6 Mil

Key Statistics

Price/Earnings (Normalized)
27.50
Price/Sales
5.41
Dividend Yield (Trailing)
0.24%
Dividend Yield (Forward)
0.26%
Total Yield
1.54%

Company Profile

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Large Core
Total Number of Employees
122,000

Competitors

Valuation

Metric
TMO
A
WAT
Price/Earnings (Normalized)
27.5025.8626.41
Price/Book Value
4.796.4414.65
Price/Sales
5.416.146.33
Price/Cash Flow
26.6621.6422.31
Price/Earnings
TMO
A
WAT

Financial Strength

Metric
TMO
A
WAT
Quick Ratio
1.191.491.39
Current Ratio
1.702.152.22
Interest Coverage
4.8315.348.28
Quick Ratio
TMO
A
WAT

Profitability

Metric
TMO
A
WAT
Return on Assets (Normalized)
8.69%14.45%17.19%
Return on Equity (Normalized)
18.71%26.40%88.59%
Return on Invested Capital (Normalized)
10.97%18.41%25.75%
Return on Assets
TMO
A
WAT
See how this stock stacks up to its competitors with Morningstar Investor

Diagnostics & Research Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Danaher Corp
DHR
JpqrthnqJpbdmf$197.8 Bil
IQVIA Holdings Inc
IQV
JmczmflKllgv$43.7 Bil
Agilent Technologies Inc
A
QrhhclsgmHvrj$39.4 Bil
IDEXX Laboratories Inc
IDXX
ZtzjsjwrrSlzxyx$38.8 Bil
Mettler-Toledo International Inc
MTD
ZwtnqbzvhXjczgn$30.1 Bil
Icon PLC
ICLR
ZzhhhmrkLmdkkdn$25.9 Bil
Illumina Inc
ILMN
RbdmdjcwpKnkmtbq$18.7 Bil
Waters Corp
WAT
WyjgzjjdpZdzd$18.4 Bil
Labcorp Holdings Inc
LH
HksfgjxvRyhskj$17.8 Bil

Sponsor Center